 |
dexrazoxane hydrochloride |
|---|---|
| Trade Name | |
| Orphan Indication | Prevention of cardiomyopathy for chilren and adolescents 0 through 16 years of age treated with anthracyclines |
| USA Market Approval | USA |
| USA Designation Date | 2014-08-19 00:00:00 |
| Sponsor | Satiscor, LLC;45 Marine Road;Boston, Massachusetts, 02127 |
